Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

Water-free cyclosporine formulation safe, effective for dry eye disease

17 Jun 2019

Treatment with water-free cyclosporine formulation (CyclASol) at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease (DED), according to data from a phase II study.

The study randomly assigned 207 DED patients (mean age, 62.4 years; 73.9 percent female) to one of the following treatment arms: CyclASol 0.05% (n=51), CyclASol 0.1% (n=51), vehicle (n=52) and cyclosporine emulsion (n=53). Dosed twice daily, the 16-week treatment was initiated after a 2-week run-in period.

Efficacy endpoints included total and subregion corneal fluorescein staining, conjunctival staining, visual analogue scale (VAS) for dry eye symptoms, VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire scores.

During the 16-week treatment period, CyclASol consistently reduced corneal and conjunctival staining compared with both the vehicle and emulsion. The onset of effect occurred early at day 14.

In mixed-effects model–based approach, the effect of CyclASol was statistically significant compared with that of the vehicle (total corneal staining, p<0.1; central corneal staining, p<0.001; conjunctival staining, p<0.01). CyclASol also demonstrated a significant effect on OSDI as symptom parameter (p<0.01).

Dryness symptoms, as measured by VAS, improved across all treatment arms, with no significant difference between CyclASol and vehicle.

In terms of safety, the rate of ocular adverse events was low in all treatment arms. Treatment-emergent adverse events were reported in 65 patients (31.4 percent) overall, all of which were mild-to-moderate in severity.

The present data show that the new water-free cyclosporine formulation relieves the signs of DED as early as after 2 weeks of treatment, with excellent safety, tolerability and comfort profile, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.